To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sigma-Aldrich Announces Agreement with IUBMB to Produce and Publish the Nicholson Metabolic Pathways Charts
24-09-2004
Sigma-Aldrich Corporation is pleased to announce its collaboration with the International Union of Biochemistry and Molecular Biology (IUBMB) to produce and publish Metabolic Pathways Charts developed by esteemed scientist Donald Nicholson, D.Sc. The agreement grants Sigma-Aldrich the ...
Biovitrum acquires promising anti-obesity drug leads from BioFocus
24-09-2004
Chesterford Research Park, UK and Stockholm, Sweden. BioFocus plc., a world leader in drug discovery, and Biovitrum today announce that Biovitrum has acquired from BioFocus the rights to a promising research project in obesity. The research project, which currently is at the end of the lead ...
JTG to Showcase Philadelphia Biotech Companies' Technology Needs at One of the Largest Technology Trade Shows in Japan
The Company Serves as a Link Between Philadelphia Biotech Companies and Untapped Japanese Innovations
23-09-2004
Japan Technology Group (JTG) - a Philadelphia-based Japanese technology licensing firm - will showcase technology needs information for pharmaceutical/biotechnology/life science corporations in the Greater Philadelphia area who seek to obtain untapped innovations emerging from Japanese ...
GeneEd Appoints Mr. Takashi Nakamura to Its Business Advisory Board
Renowned Executive to Contribute to the Development of GeneEd's Life Science e-Learning Business in Far East
23-09-2004
GeneEd, the leading provider of e-Learning solutions for Life Sciences, announced the appointment of Mr. Takashi Nakamura to its Business Advisory Board. Mr. Nakamura is a highly successful entrepreneur with executive-level experience in international business development, strategic ...
Wilex starts clinical trial with new anti-cancer compound
23-09-2004
Wilex AG, Munich, a privately held biopharmaceutical company dedicated to the development of novel cancer therapies, today announced that it has started a "first into man" clinical Phase I trial with its new oral non-cytotoxic anti-cancer compound WX-671. The open-label dose escalating study ...
Affymetrix Technology to Be Used in Groundbreaking Studies of Neurological Disease
GeneChip(R) Microarray Technology Enabling Perlegen Sciences to Study Alzheimer's Disease, Autism and Parkinson's Disease
22-09-2004
Affymetrix GeneChip technology is now enabling three unprecedented studies of complex brain disease. Perlegen Sciences recently announced that they are using high density Affymetrix GeneChip microarrays for landmark studies of the genetic causes of Alzheimer's disease, autism, and Parkinson's ...
NIH licenses GenomatixSuite access for intramural researchers
22-09-2004
Munich. Genomatix Software GmbH announces that it signed a license agreement with NCI, allowing 100 intramural researchers at all of the 21 NIH institutes full and unlimited access to GenomatixSuite. GenomatixSuite integrates software and databases designed for analysis of gene regulatory ...
WPI Bioengineering Institute Develops Program to Meet Medical Device Industry's Demand for Qualified Employees
22-09-2004
Waltham, Mass. - The Worcester Polytechnic Institute (WPI) Bioengineering Institute announces the development of a new 11-week, evening educational program designed to help working professionals learn about the medical device industry. Developed in cooperation with the Massachusetts Medical ...
Global Genomics ab signs collaboration agreement with Rheoscience A/S
22-09-2004
Global Genomics(SM) AB (Stockholm, Sweden) announced today that Rheoscience A/S (Roedovre, Denmark) has entered into an agreement for the use tangerine® gene expression profiling to study targets in metabolic diseases. Ulf Boberg, CEO at Global Genomics stated, "This agreement is yet another ...
Roche and GLYCART to discover new therapeutic antibodies
22-09-2004
Roche and GLYCART biotechnology today announced an agreement to discover next-generation therapeutic antibodies using GlycoMAbTM technology. Roche will have the option to develop and market worldwide all antibodies generated by GLYCART from an undisclosed product candidate. GLYCART will ...
Netmeeting
